Literature DB >> 22406279

Safety reporting in developing country vaccine clinical trials-a systematic review.

Susann Muehlhans1, Georgina Richard, Mohammad Ali, Gabriela Codarini, Chris Elemuwa, Ali Khamesipour, Wolfgang Maurer, Edison Mworozi, Sonali Kochhar, Gabriella Rundblad, Dominique Vuitton, Barbara Rath.   

Abstract

With more vaccines becoming available worldwide, vaccine research is on the rise in developing countries. To gain a better understanding of safety reporting from vaccine clinical research in developing countries, we conducted a systematic review in Medline and Embase (1989-2011) of published randomized clinical trials (RCTs) reporting safety outcomes with ≥50% developing country participation (PROSPERO systematic review registration number: CRD42012002025). Developing country vaccine RCTs were analyzed with respect to the number of participants, age groups studied, inclusion of safety information, number of reported adverse events following immunization (AEFI), type and duration of safety follow-up, use of standardized AEFI case definitions, grading of AEFI severity, and the reporting of levels of diagnostic certainty for AEFI. The systematic search yielded a total number of 50 randomized vaccine clinical trials investigating 12 different vaccines, most commonly rotavirus and malaria vaccines. In these trials, 94,459 AEFI were reported from 446,908 participants receiving 735,920 vaccine doses. All 50 RCTs mentioned safety outcomes with 70% using definitions for at least one AEFI. The most commonly defined AEFI was fever (27), followed by local (16) and systemic reactions (14). Logistic regression analysis revealed a positive correlation between the implementation of a fever case definition and the reporting rate for fever as an AEFI (p=0.027). Overall, 16 different definitions for fever and 7 different definitions for erythema were applied. Predefined AEFI case definitions by the Brighton Collaboration were used in only two out of 50 RCTs. The search was limited to RCTs published in English or German and may be missing studies published locally. The reported systematic review suggests room for improvement with respect to the harmonization of safety reporting from developing country vaccine clinical trials and the implementation of standardized case definitions.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22406279     DOI: 10.1016/j.vaccine.2012.02.059

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Innovative Digital Tools and Surveillance Systems for the Timely Detection of Adverse Events at the Point of Care: A Proof-of-Concept Study.

Authors:  Christian Hoppe; Patrick Obermeier; Susann Muehlhans; Maren Alchikh; Lea Seeber; Franziska Tief; Katharina Karsch; Xi Chen; Sindy Boettcher; Sabine Diedrich; Tim Conrad; Bron Kisler; Barbara Rath
Journal:  Drug Saf       Date:  2016-10       Impact factor: 5.606

2.  Safety profile of the meningococcal conjugate vaccine (Menafrivac™) in clinical trials and vaccination campaigns: a review of published studies.

Authors:  Jerome Ateudjieu; Beat Stoll; Anne Cecile Bisseck; Ayok M Tembei; Blaise Genton
Journal:  Hum Vaccin Immunother       Date:  2019-09-05       Impact factor: 3.452

3.  Awareness and utilization of reporting pathways for adverse events following immunization: online survey among pediatricians in Russia and Germany.

Authors:  Susann Muehlhans; Max von Kleist; Tatiana Gretchukha; Martin Terhardt; Ulrich Fegeler; Wolfgang Maurer; Leila Namazova-Baranova; Gerhard Gaedicke; Alexander Baranov; Barbara Rath
Journal:  Paediatr Drugs       Date:  2014-08       Impact factor: 3.022

4.  Enabling Precision Medicine With Digital Case Classification at the Point-of-Care.

Authors:  Patrick Obermeier; Susann Muehlhans; Christian Hoppe; Katharina Karsch; Franziska Tief; Lea Seeber; Xi Chen; Tim Conrad; Sindy Boettcher; Sabine Diedrich; Barbara Rath
Journal:  EBioMedicine       Date:  2016-01-12       Impact factor: 8.143

5.  Using Mobile Technology (pMOTAR) to Assess Reactogenicity: Protocol for a Pilot Randomized Controlled Trial.

Authors:  Kathryn Therese Mngadi; Bhavna Maharaj; Yajna Duki; Douglas Grove; Jessica Andriesen
Journal:  JMIR Res Protoc       Date:  2018-10-03

6.  Advancing challenges in Paediatric Virology: An interview with Professor Barbara A. Rath, Co-founder and Chair of the Vienna Vaccine Safety Initiative.

Authors:  Ioannis N Mammas; Demetrios A Spandidos
Journal:  Exp Ther Med       Date:  2019-08-28       Impact factor: 2.447

7.  Development and validation of a questionnaire for the assessment of the knowledge, management and reporting ADR in paediatrics by healthcare teams (QUESA-P).

Authors:  Sheilla S Tavares; Luciane N Cruz; Juliana Castro; Luciane Cruz Lopes
Journal:  BMJ Open       Date:  2019-10-17       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.